Position in NGEN
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$20,600
-$17,100 QoQ
Shares Held
10,000
0.0% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#53
of 62 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NGEN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Paladin Partners, LLC holds $72,561 across 6 Biotechnology names. NGEN ranks #2 (28.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GLUE |
Monte Rosa Therapeutics, Inc.
|
1,000 | $24,200 | |
| 2 | NGEN |
Nervgen Pharma Corp.
This page
|
10,000 | $20,600 | |
| 3 | INKT |
MiNK Therapeutics, Inc.
|
1,000 | $11,690 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
150 | $8,181 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
200 | $7,802 | |
| 6 | CRBU |
Caribou Biosciences, Inc.
|
50 | $88 |
All Filings in NGEN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20,600 | 10,000 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $37,700 | 10,000 | Shares | Sole | 2026-06-25 | |
| 2025-12-31 | $56,000 | 10,000 | Shares | Sole | 2026-06-25 | |
| No filing history on record for this holder in this stock. | ||||||